clinical trial · NCT05063162
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
UCB Biopharma SRL·phase3·active not recruiting·n = 104
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)RozanolixizumabPlacebo
brief summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
started
Feb 2, 2022
primary completion
May 6, 2027
completion
Jul 1, 2027
last updated
Mar 13, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol